Get the Stockscreener App
2.77
2.59%
0.07
After Hours:
2.90
0.13
+4.69%
Vyne Therapeutics Inc stock is traded at $2.77, with a volume of 183.64K.
It is up +2.59% in the last 24 hours and up +10.80% over the past month.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$2.70
Open:
$2.72
24h Volume:
183.64K
Relative Volume:
1.51
Market Cap:
$40.86M
Revenue:
$486.00K
Net Income/Loss:
$-28.43M
P/E Ratio:
-0.9827
EPS:
-2.8189
Net Cash Flow:
$-26.75M
1W Performance:
+0.73%
1M Performance:
+10.80%
6M Performance:
+30.05%
1Y Performance:
+55.62%
1-Day Range:
$2.65
$3.08
1-Week Range:
$2.57
$3.08
52-Week Range:
$1.57
$4.30
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Name
Vyne Therapeutics Inc
Sector
Industry
Phone
800-775-7936
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
2.77 | 40.86M | 486.00K | -28.43M | -26.75M | -2.8189 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | BTIG Research | Buy |
| Dec-06-21 | Resumed | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Stock (VYNE) Latest News
VYNE Therapeutics Updates Corporate Presentation and Pipeline Progress - Defense World
Vyne therapeutics director Patrick Lepore buys $43,800 in stock By Investing.com - Investing.com Australia
Vyne therapeutics director Patrick Lepore buys $43,800 in stock - Investing.com India
Insider Buying: Patrick Lepore Acquires 15,000 Shares of VYNE Th - GuruFocus.com
VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright - MarketBeat
Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail
Financial Analysis: Skye Bioscience (NASDAQ:SKYE) vs. VYNE Therapeutics (NASDAQ:VYNE) - Defense World
VYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligo - Yahoo Finance
VYNE Therapeutics’ (VYNE) Buy Rating Reaffirmed at HC Wainwright - Defense World
Forecasting The Future: 4 Analyst Projections For VYNE Therapeutics - Benzinga
VYNE Therapeutics' (VYNE) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo - Marketscreener.com
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluat - WICZ
VYNE Therapeutics Completes Phase 2b Trial Enrollment for Novel Vitiligo Treatment VYN201 - StockTitan
VYNE stock soars to 52-week high, touches $3.43 By Investing.com - Investing.com South Africa
VYNE stock soars to 52-week high, touches $3.43 - Investing.com
VYNE Therapeutics Reports Positive Phase 1a MAD Data for VYN202 - Defense World
H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data - Yahoo Finance
VYNE Therapeutics’ (VYNE) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
VYNE Therapeutics Reports Positive Phase 1a MAD Data for BD2-Selective BET Inhibitor VYN202 - Dermatology Times
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor - The Manila Times
Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Drops By 37.1% - Defense World
VYNE Therapeutics Sees Strong Shareholder Support for Growth - TipRanks
Prurigo Nodularis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therap - The Globe and Mail
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates - MSN
VYNE Therapeutics initiated with a Buy at BTIG on I&I potential - Yahoo Finance
BTIG Initiates Coverage of VYNE Therapeutics (VYNE) with Buy Recommendation - MSN
VYNE Therapeutics’ (VYNE) Buy Rating Reiterated at HC Wainwright - Defense World
VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
VYNE Therapeutics Advances Clinical Pipeline in Q3 2024 - TipRanks
VYNEVYNE Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
VYNE Therapeutics Reports Strong Pipeline Progress, $70.2M Cash Position Despite Q3 Loss | VYNE Stock News - StockTitan
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate - Simply Wall St
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully - Yahoo Finance
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates - MSN
Shapiro Capital Management LLC Makes New Investment in NCR Voyix Co. (NYSE:VYX) - Defense World
(VYX) Long Term Investment Analysis - Stock Traders Daily
Engine Capital Management LP Purchases Shares of 78,691 NCR Voyix Co. (NYSE:VYX) - MarketBeat
ZIGUP plc Optimistic as Vehicle Supply Improves - TipRanks
ZIGUP plc Optimistic as Vehicle Supply Rises - TipRanks
Wix Is Set for Growth With Expanding Margins and Cash Flow, Analyst Upgrades Stock - Benzinga
What is Voyager Therapeutics Inc (VYGR) Stock Return on Shareholders’ Capital? - SETE News
Wix, GoDaddy in spotlight as Piper Sandler changes ratings on pair - Seeking Alpha
Wix.com (NASDAQ:WIX) Upgraded by Piper Sandler to "Overweight" - MarketBeat
Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World
Xylem Inc. (NYSE:XYL) Shares Sold by Virtu Financial LLC - Defense World
A company insider recently bought 3,648 shares of NCR Voyix Corp [VYX]. Should You Buy? - Knox Daily
HC Wainwright Reiterates Buy Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World
VYNE reports positive early trial results for inflammation drug - Investing.com
Vyne Therapeutics Inc Stock (VYNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):